Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s):  CPHRF

Healthcare
Cipher Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products either directly in Canada or indirectly through partners in Canada, the United States and South America. Its Dermatology products include Actikerall, Epuris, Ozanex and Vaniqa. Its Hospital Acute Care products include Aggrastat and Brinavess. Its Out-Licensed products include Absorica, ConZip and Lipofen. The Company is also focused on building a portfolio of prescription medicines that serve unmet medical needs. The Company's product pipeline development programs including MOB-015, DTR-001, and CF-101. The Company's subsidiaries include Cipher US Holdings Inc., Cipher US Holdco LLC, and Cipher Pharmaceuticals US LLC.


TSX:CPH - Post by User

Cipher Pharmaceuticals Inc > distribution deals next week?
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(28)
•••
Comment by spike55on Oct 01, 2020 4:30pm
114 Views
Post# 31652879

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:distribution deals next week?

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:distribution deals next week?
shareswapper wrote: Ya I know nothing, what I do know is they LONG AGO completed the strategic review and concluded that a distribution partner(s) for Canada was the best option.  It has since been delayed, now the company has missed guidance that it would happen in September.  The Generic entrant date is looming and the company is "crickets".  Keep your head in the Sand as long as you want Oscar .......


Thats right the reason is simple for most COVID



<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities